Acute Ischaemic Stroke
Conditions
Brief summary
This is a randomized,controlled, double-blinded, phase 3 clinical study to evaluate the efficacy and safety of recombinant human urokinase(rhPro-UK) versus basic treatment for patients with acute ischaemic stroke in 4.5-6 hours after stroke onset.
Interventions
Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
DRUGAspirin
Aspirin 300mg is taken orally at the beginning of thrombolysis.
DRUGrhPro-UK simulation agent
Patients receive rhPro-UK simulation agent 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
DRUGAspirin simulation agent
Aspirin simulation agent 300mg is taken orally at the beginning of thrombolysis.
Sponsors
Tasly Biopharmaceuticals Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Ischemic stroke with symptoms of neurological deficits. 2. Aged 18 to 80 years,male or famale. 3. NIH Stroke Scale（NIHSS）scores of 4 to 25. 4. Treatment 4.5 to 6 hours after stroke onset.(Stroke onset time is defined as the last time a patient with no clinical neurological deficit,for patients who wake up with stroke symptoms, consider that stroke occurs when the patient begins to fall asleep). 5. The symptoms of stroke last at least 30 minutes without significant improvement before treatment. 6. CT showed negative or signs of early infarction. 7. Patients and/or their families are willing to participate in this study and agree to sign informed consent.
Exclusion criteria
1. Patients with premorbid modified Rankin Scale(mRS) score ≥2 2. CT showed multiple infarctions（low density\> 1/3 cerebral hemisphere）. 3. Transient ischemic attack. 4. Epileptic seizure when stroke onset. 5. Intracranial tumor, arteriovenous malformation and aneurysm. 6. Iatrogenic Stroke. 7. Thrombectomy is planned. 8. Cardioembolism and atrial fibrillation. 9. Myocardial infarction history within 3 months. 10. Severe cerebral trauma or stroke history within 3 months. 11. Blood pressure is still out of control after aggressive antihypertensive treatment.Uncontrolled blood pressure is defined as systolic blood pressure≥ 180mmHg or diastolic blood pressure≥100mmHg. 12. High density lesions (bleeding) and subarachnoid hemorrhage is revealed by emergency CT examination. 13. Active visceral hemorrhage. 14. Patients with intracerebral hemorrhage history. 15. Patients with diabetic retinopathy history. 16. Puncture in 1 week which can not be oppressed. 17. Major surgery or severe trauma within 2 weeks. 18. Intracranial surgery, intraspinal surgery or solid organ biopsy within 30 days. 19. Heparin treatment within 48 hours (APTT above normal upper limit). 20. Taking anticoagulant drugs orally, and PT \>15s or INR \>1.7. 21. High risk of acute hemorrhage include platelet count\<10\^9/L. 22. Taking thrombin inhibitors or factor Xa inhibitor with abnormal results of sensitive laboratory examination(e.g. APTT, INR, PLT, FIB、TT or appropriate Ⅹ a factor activity test, etc.). 23. Blood glucose \< 2.7 mmol/L or \> 22.2 mmol/L. 24. Pregnancy, lactating or menstrual women. 25. Patients who have difficulty swallowing and are unable to take medications orally. 26. Clinician thinks patient doesn't fit to participate in the test of other diseases or conditions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Functional handicap | 90days | Proportion of patients achieving a Modified Rankin Scale(mRS,which has a range of 0 to 6, with 0 indicating no symptoms at all and 6 indicating death) of 0 to 1 at 90 days after treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Scores of Neurological Improvement | 24 hours | NIHSS changes from baseline at 24 hours after treatment |
| Index Long-term Change from Baseline of Barthel Index | 90 days | Barthel Index(which assesses the ability to perform activities of daily living, on a scale that ranges from 0 to 100) changes from baseline on 90 days after treatment. |
| Long-term Change from Baseline of NIHSS | 90 days | NIHSS changes from baseline on 90 days after treatment. |
| Long-term Change from Baseline of mRS | 90 days | mRS changes from baseline on 90 days after treatment. |
| Proportion of Neurological Improvement | 90 days | Proportion of patients achieving a NIHSS(national institutes of health stroke scale) ≦1 or reduction of ≥4 NIHSS points at 24 hours after treatment. |
| Systemic hemorrhage | 90days | Severe systemic hemorrhage |
| Symptomatic intracerebral hemorrhage | 90days | Symptomatic intracerebral hemorrhage (sICH) |
| Death | 7 days and 90 days | Death |
| Recurrence | 7 days | Recurrence of stroke |
| Proportion of Long-term Improvement | 90 days | Proportion of patients achieving a mRS of 0 to 2 at 90 days after treatment. |
Countries
China
Outcome results
None listed